Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters

新增60,000升药物原料产能，总产能达到845,000升。

Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support

标志着三星生物制品公司的地域多元化，并建立了其首个美国制造基地，扩大了区域客户支持。

Plans further investments to add capabilities and strengthen long-term operations at the Rockville site

计划进一步投资，以增加能力并加强罗克维尔工厂的长期运营。

INCHEON, South Korea and ROCKVILLE, MD.

韩国仁川和美国马里兰州罗克维尔市

,

，

March 31, 2026

2026年3月31日

/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States..

/PRNewswire/ -- 领先的合同开发和制造组织（CDMO）三星生物制品公司（Samsung Biologics，KRX: 207940.KS）今天宣布，已完成从GSK收购位于美国马里兰州罗克维尔的生产设施，标志着该公司在美国的首个生产基地正式成立。

The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics' total global manufacturing capacity increases to 845,000 liters..

罗克维尔工厂包括两个符合现行药品生产管理规范（cGMP）的生产厂，总药物原料产能达60,000升，支持多种生产规模的临床和商业生物制品生产。通过此次扩展，三星生物制剂的全球总生产能力增加至845,000升。

Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional contract manufacturing needs. Samsung Biologics also plans further investments to expand the site's capacity and upgrade technologies, reinforcing its long-term commitment to advancing a more resilient global supply chain and improving patient access to critical medicines..

三星生物将继续根据协议条款向GSK供应此前在该工厂生产的产品，同时该工厂将转型以满足更多的合同生产需求。三星生物还计划进一步投资，扩大工厂产能并升级技术，强化其对提升全球供应链弹性的长期承诺，并改善患者获取关键药物的途径。

'This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family,' said John Rim, President and CEO of Samsung Biologics.

“这代表着我们扩大美国制造基地的一个重要步骤。新增的罗克维尔工厂增强了我们运营地理多样化制造网络的能力，我们非常高兴正式欢迎该厂的500多名同事加入三星生物制品大家庭，”三星生物制品总裁兼首席执行官John Rim表示。

'The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.'.

“罗克维尔团队带来了深厚的专业知识和强大的运营经验，这将进一步加强该基地作为我们全球制造网络的一部分。作为CDMO，我们的使命是帮助合作伙伴将重要的治疗方法带给全世界的患者，该基地将在实现这一使命中发挥关键作用，同时确保连续性并坚持客户期望的高标准。”

The completion follows the previously announced agreement to acquire the facility on December 22, 2025.

完成收购设施的协议之前已于2025年12月22日宣布。

About Samsung Biologics Co., Ltd.

关于三星生物制品有限公司

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

三星生物制品（KRX: 207940.KS）是一家领先的合同开发和制造组织（CDMO），提供从后期发现到商业生产的端到端综合服务。

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities..

三星生物制药公司在韩国的Bio Campus I和II拥有总计785,000升的生物制造能力，并通过收购美国马里兰州罗克维尔的一家制造工厂获得60,000升的产能，因此其全球总制造能力达到845,000升。公司还为Bio Campus III购入了土地，为未来产能扩展、支持下一代疗法和新兴模式奠定了基础。

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

三星生物制品公司利用尖端技术和专业知识，推进多种模式的发展，包括多特异性抗体、融合蛋白、抗体药物偶联物和mRNA疗法。

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

通过在其制造网络中实施ExellenS™框架，采用标准化设计、统一的流程和先进的数字化技术，三星生物制品公司确保了工厂的等效性和生产连续性的速度。

Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients.

三星生物制品公司的全球制造和商业网络覆盖韩国、美国和日本。三星生物制品美国公司为基于美国和欧洲的客户提供支持，而其东京销售办事处则服务于亚太地区。三星生物制品公司持续投资于新能力，以最大化运营和质量卓越性，确保为客户提供灵活性和敏捷性。

The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health..

公司致力于准时、全额交付安全、高质量的生物医学产品，并致力于为社会和全球健康做出可持续的商业决策。

For more information, visit

欲了解更多信息，请访问

https://samsungbiologics.com/

https://samsungbiologics.com/

Media contacts

媒体联系人

Samsung Biologics

三星生物制品

Claire Kim, Senior Director

克莱尔·金，高级总监

[email protected]

电子邮件地址

Becky Lee, Director

贝琪·李，主任

[email protected]

电子邮件地址

SOURCE Samsung Biologics

来源：三星生物制品公司

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示